【摘要】 ３９例慢性肝炎患者，其中乙型肝炎１２例，丙型肝炎２７例，接受人α＿１型基因工程干扰素治疗（ｒＨＩＦＮα＿１）。１０例丙型肝炎病人ｒＨＩＦＮα＿１每日肌注１×１０￣６Ｕ，连用９０天，１７例丙型肝炎病人和乙型肝炎ｒＨＩＦＮα＿１每日肌注３×１０￣６Ｕ，连用９０天。治疗后乙型肝炎组ＨＢｅＡｇ和ＨＢＶＤＮＡ的阴转率均为４１．６７％；丙型肝炎用１×１０￣６Ｕ／ｄ和３×１０￣６Ｕ／ｄ组ＨＣＶＲＮＡ阴转率分别为５０％和６４．７％，两个剂量组阴转率比较差异无显著性（Ｐ＞０．０５），治疗期间不良反应发生率较低，远期疗效尚待观察。更多还原

【Abstract】 A total of 32 patients with chronic viral hepatitis were treated using recombi-nant human alpha 1- interferon（rHIFNaα₁）.Of these 10 chronic hepatitis C（CHC）were inject-ed intramuscularlv 1 million international unit（MIU）of rHIFNα₁ once a day for ninty days;17 chronic hepatitis C and 12 chronic hepatitis B（CHB）patients,3 MIU rHIFNα₁ once a dayfor ninty days. At the end of the therapeutic couse there were 41. 67%of patients with CHBwho had a seroconversion of HBeAg and HBV DNA. HCV RNA in sera detected by PCR dis-appeared in 50%in patients with CHC recived 1 MIU rHIFNα₁,64.7%in those recived 3MIU rHIFNα₁ respectively. The differance between the proportions of seroconversion of HCVRNA was not statistically significant（ P>0.05）.Side effects of rHIFNα₁ were moderate.Some more work is needed for observeing further responses.更多还原